Compare Stocks → The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:MRKRNASDAQ:OASM Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMRKRMarker Therapeutics$4.19+1.2%$4.26$0.76▼$9.68$36.86M1.520,783 shs14,370 shsOASMOasmia Pharmaceutical AB (publ)$0.02$1.46$0.94▼$5.70$1.50M0.9698,414 shsN/A7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMRKRMarker Therapeutics+1.21%-5.63%-14.66%-3.90%+331.96%OASMOasmia Pharmaceutical AB (publ)0.00%0.00%0.00%0.00%-60.00%The A.I. story nobody is telling you (Read ASAP) (Ad)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMRKRMarker TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOASMOasmia Pharmaceutical AB (publ)N/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMRKRMarker TherapeuticsN/AN/AN/AN/AOASMOasmia Pharmaceutical AB (publ)N/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMRKRMarker Therapeutics$3.31M11.27N/AN/A$1.58 per share2.65OASMOasmia Pharmaceutical AB (publ)$220K6.82N/AN/A$0.63 per share0.03Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMRKRMarker Therapeutics-$8.24MN/A0.00∞N/A-142.62%-39.89%-25.45%5/21/2024 (Estimated)OASMOasmia Pharmaceutical AB (publ)-$18.95MN/A0.00∞N/A-8,633.64%-43.94%-28.92%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMRKRMarker TherapeuticsN/AN/AN/AN/AN/AOASMOasmia Pharmaceutical AB (publ)N/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMRKRMarker TherapeuticsN/A5.575.57OASMOasmia Pharmaceutical AB (publ)N/A0.800.73OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMRKRMarker Therapeutics22.39%OASMOasmia Pharmaceutical AB (publ)0.11%Insider OwnershipCompanyInsider OwnershipMRKRMarker Therapeutics24.10%OASMOasmia Pharmaceutical AB (publ)N/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableMRKRMarker Therapeutics88.90 million6.76 millionNot OptionableOASMOasmia Pharmaceutical AB (publ)5774.97 millionN/ANot OptionableOASM and MRKR HeadlinesSourceHeadlineLipigon Pharmaceuticals AB LPGOmorningstar.com - March 23 at 12:53 AMLSK BioPartners, Inc., Oasmia Pharmaceutical AB (publ) - Special Call Transcriptgurufocus.com - March 6 at 9:00 AMOasmia Pharmaceutical AB (publ) - Special Call Transcriptgurufocus.com - March 6 at 9:00 AMResurs Holding AB (publ) (RESURS.ST)finance.yahoo.com - February 8 at 12:32 AMQuiaPEG Pharmaceuticals Holding AB QUIAmorningstar.com - January 6 at 5:30 PMNewbury Pharmaceuticals AB (NEWBRY)investing.com - November 29 at 2:08 AMDentsu Creative bags mandate for Torrent Pharmaceuticals’ Shelcal & Unienzymebestmediainfo.com - September 26 at 1:06 AMLipigon Pharmaceuticals AB (LPGO)investing.com - September 14 at 9:09 AMSpeqta publ AB (SPEQT)investing.com - August 25 at 9:50 PMPRXXF Paradox Interactive AB (publ)seekingalpha.com - August 25 at 9:29 AMNotice of annual general meeting in Alzinova AB (publ)privataaffarer.se - April 25 at 8:37 AMReport from Annual General Meeting 2023 of PowerCell Sweden AB (publ)privataaffarer.se - April 21 at 8:26 PMNotice of Annual General Meeting 2023 in Enzymatica AB (publ) (2)europapress.es - April 2 at 9:53 AMOXE Marine AB (publ) Non-GAAP EPS of -SEK0.43, revenue of SEK32.2Mseekingalpha.com - February 26 at 11:56 PMUS regulators clear way for more monkeypox vaccine shipmentsstarherald.com - July 14 at 11:12 AMPRELIMINARY RESULT OF OASMIA’S RIGHTS ISSUE (MFN)avanza.se - March 24 at 6:47 AMOasmia expands R&D ability with planned laboratory upgradeprivataaffarer.se - March 17 at 8:40 AMOrexo appoints Fredrik Järrsten as new CFOstockhouse.com - March 11 at 3:47 AMNotice of extra general meeting in Terranet ABfinanznachrichten.de - November 29 at 10:24 AMPet Cancer Therapeutics Market – Know-How Industry to Experience Positive Growth | robust CAGR of 7.7% over the forecast period (2017 – 2025).medgadget.com - September 17 at 2:52 AMVeterinary Cancer Therapeutics Market Segmentation, Size Analysis, Key Players Forecast To 2027openpr.com - July 28 at 7:04 PMFancy Wood Industries PCL (FANCY)investing.com - July 22 at 7:07 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsMarker TherapeuticsNASDAQ:MRKRMarker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company also develops MT-401-OTS, which is in phase 1 clinical trial for the treatment of acute myeloid leukemia; and MT-601 which is in phase 1 clinical trial for the treatment of lymphoma, as well as in phase 1/2 clinical trial for the treatment of pancreatic cancer. Marker Therapeutics is headquartered in Houston, Texas.Oasmia Pharmaceutical AB (publ)NASDAQ:OASMOasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.